Status:
COMPLETED
Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
Lead Sponsor:
Bayer
Conditions:
Computed Tomography
Diagnostic Imaging
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist...
Detailed Description
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc. Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Is at least 18 years old and clinically indicated for a contrast-enhanced CT of the head or body.
Exclusion
- Patients that are less than 18 years old and do not have a clinical indication for a contrast-enhanced CT of the head or body.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
435 Patients enrolled
Trial Details
Trial ID
NCT00244140
Start Date
October 1 2005
End Date
April 1 2008
Last Update
February 28 2014
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson, Arizona, United States, 85711
2
Miami, Florida, United States, 33101
3
Tallahassee, Florida, United States, 32308
4
Atlanta, Georgia, United States, 30303